Fibrinogen, mortality and incident cardiovascular complications in end-stage renal failure

被引:75
作者
Zoccali, C
Mallamaci, F
Tripepi, G
Cutrupi, S
Parlongo, S
Malatino, LS
Bonanno, G
Rapisarda, F
Fatuzzo, P
Seminara, G
Stancanelli, B
Nicocia, G
Buemi, M
机构
[1] CNR, Inst Biomed Clin Epidemiol & Pathophysiol Renal D, Reggio Di Calabria, Italy
[2] Univ Catania, Dept Internal Med, L Condorelli Inst, I-95124 Catania, Italy
[3] Univ Messina, Clin Pathol Unit, I-98100 Messina, Italy
[4] Univ Messina, Nephrol Chair, I-98100 Messina, Italy
关键词
C-reactive protein; cardiovascular risk; dialysis; fibrinogen; inflammation; uremia;
D O I
10.1046/j.1365-2796.2003.01180.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Fibrinogen is an established predictor of cardiovascular events in the general population but the relationship between fibrinogen, mortality and incident cardiovascular complications has been very little investigated in patients with end-stage renal disease (ESRD). Design and subjects. We investigated the relationship between fibrinogen and all cause mortality and cardiovascular outcomes in a prospective cohort study in 192 patients on chronic haemodialysis treatment (follow-up: 34 +/- 16 months). Results. Fibrinogen was significantly higher in patients who died during the follow-up than in those who survived. Similarly, fibrinogen was higher in patients who had fatal or nonfatal cardiovascular events than in event free patients. On multivariate Cox regression analysis fibrinogen was an independent predictor of survival [hazard ratio (1 g L-1 increase in plasma fibrinogen): 1.19, 95% confidence interval (CI): 1.05-1.35, P = 0.006] and a highly significant (P = 0.0008), independent predictor of fatal and nonfatal cardiovascular events [hazard ratio (1 g L-1 increase in plasma fibrinogen): 1.25, 95% CI: 1.10-1.43] in a model including traditional risk factors and serum C-reactive protein (CRP) and plasma homocysteine. Conclusions. Fibrinogen is as an independent risk factor for overall and cardiovascular mortality in patients with ESRD. Intervention studies are required to see whether reducing plasma fibrinogen may help to curb the exceedingly high cardiovascular risk of the uremic population.
引用
收藏
页码:132 / 139
页数:8
相关论文
共 40 条
[21]  
LEE AJ, 1993, BRIT HEART J, V69, P338
[22]  
Lysaght MJ, 2002, J AM SOC NEPHROL, V13, pS37
[23]   Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients [J].
Mallamaci, F ;
Zoccali, C ;
Tripepi, G ;
Fermo, I ;
Benedetto, FA ;
Cataliotti, A ;
Bellanuova, I ;
Malatino, LS ;
Soldarini, A .
KIDNEY INTERNATIONAL, 2002, 61 (02) :609-614
[24]   FIBRINOLYTIC-ACTIVITY, CLOTTING FACTORS, AND LONG-TERM INCIDENCE OF ISCHEMIC-HEART-DISEASE IN THE NORTHWICK-PARK-HEART-STUDY [J].
MEADE, TW ;
RUDDOCK, V ;
STIRLING, Y ;
CHAKRABARTI, R ;
MILLER, GJ .
LANCET, 1993, 342 (8879) :1076-1079
[25]   HEMOSTATIC FUNCTION AND ISCHEMIC-HEART-DISEASE - PRINCIPAL RESULTS OF THE NORTHWICK-PARK-HEART-STUDY [J].
MEADE, TW ;
BROZOVIC, M ;
CHAKRABARTI, RR ;
HAINES, AP ;
IMESON, JD ;
MELLOWS, S ;
MILLER, GJ ;
NORTH, WRS ;
STIRLING, Y ;
THOMPSON, SG .
LANCET, 1986, 2 (8506) :533-537
[26]   Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease [J].
Moustapha, A ;
Naso, A ;
Nahlawi, M ;
Gupta, A ;
Arheart, KL ;
Jacobsen, DW ;
Robinson, K ;
Dennis, VW .
CIRCULATION, 1998, 97 (02) :138-141
[27]  
Oda H, 2000, Adv Perit Dial, V16, P152
[28]  
PETO R, 1976, NATURAL HIST CHRONIC, P218
[29]  
Ridker P M, 1999, Blood Coagul Fibrinolysis, V10 Suppl 1, pS9
[30]  
Sechi LA, 2000, THROMB HAEMOSTASIS, V84, P565